<DOC>
	<DOCNO>NCT01008943</DOCNO>
	<brief_summary>The Autologous Cell Therapy Female SUI study clinical trial determine safety potential effectiveness single dose 200 million Cook MyoSite Autologous Muscle Derived Cells treatment Stress Urinary Incontinence .</brief_summary>
	<brief_title>Autologous Cell Therapy Female Stress Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>SUI normal detrusor activity confirm urodynamics Bladder capacity &gt; 200 ml Incontinence show improvement least 6 month Failed prior treatment ( e.g. , behavior modification , bladder exercise , biofeedback , electrical stimulation , bulk injection , urethral suspension and/or drug therapy ) Known vesicoureteral reflux , vaginal prolapse beyond introitus , significant pelvic floor abnormality high pressure instability Neuromuscular disorder ( e.g. , muscular dystrophy , multiple sclerosis ) Uncontrolled diabetes Pregnant , lactate , plan become pregnant course study Morbid obesity ( defined 100 pound ideal body weight , BMI â‰¥40 ) expect benefit treatment Current acute condition involve cystitis urethritis Scheduled receive radiation treatment vicinity , history radiation treatment urethra adjacent structure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>